| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,846,143 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
37,076 |
| Total Sell Value |
$0 |
$0 |
$0 |
$60,923 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
5 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marxe Austin W & Greenhouse David M |
10% Owner |
– – • |
2011-03-30 |
4 |
S |
$1.17 |
$292,500 |
I/I |
(250,000) |
20,375,400 |
|
- |
|
| Marxe Austin W & Greenhouse David M |
10% Owner |
– – • |
2011-02-02 |
4 |
S |
$1.34 |
$679,450 |
I/I |
(505,000) |
20,625,400 |
|
- |
|
| Marxe Austin W & Greenhouse David M |
10% Owner |
– – • |
2011-01-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,130,400 |
|
- |
|
| Rassas Kevin |
Sr. VP Business Development |
• – – |
2009-11-16 |
4 |
OE |
$0.05 |
$120,998 |
D/D |
608,344 |
726,088 |
|
- |
|
| Collins Morton |
Director |
– • – |
2009-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
215,864 |
|
- |
|
| Kim Jong Joseph |
Chief Executive OfficerOfficer |
• • – |
2009-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,841,272 |
|
- |
|
| Rassas Kevin |
Sr. VP Business DevelopmentOff |
• – – |
2009-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
117,744 |
|
- |
|
| Ng Tee Khiang |
Director |
– • – |
2009-04-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,893,004 |
|
- |
|
| Ng Tee Khiang |
Director |
– • – |
2009-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,113,923 |
|
- |
|
| Chong Chin Cheong |
Director |
– • – |
2008-12-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
148,709 |
|
- |
|
| Gan Beng Lee |
Director |
– • – |
2008-05-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
823,045 |
|
- |
|
| Rietiker Stephen |
Director |
– • – |
2008-02-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
300,000 |
|
- |
|
| Dhillon Avtar S |
President & CEO |
• • – |
2008-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
210,206 |
|
- |
|
| Dhillon Punit |
VP, Finance & OperationsOffice |
• – – |
2008-01-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
185 |
|
- |
|
| Fons Michael |
VP, Corporate DevelopmentOffic |
• – – |
2007-08-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25 |
|
- |
|
| Dhillon Avtar S |
President & CEO |
• • – |
2007-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
135,206 |
|
- |
|
| Dhillon Avtar S |
President & CEO |
• • – |
2007-03-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(75,000) |
60,206 |
|
- |
|
| Dhillon Avtar S |
President & CEO |
• • – |
2007-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
135,206 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2006-12-20 |
4 |
S |
$3.20 |
$14,080 |
D/D |
(4,400) |
0 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2006-12-20 |
4 |
OE |
$2.52 |
$11,088 |
D/D |
4,400 |
0 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2006-12-19 |
4 |
S |
$3.20 |
$137,920 |
D/D |
(43,100) |
0 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2006-12-19 |
4 |
OE |
$1.00 |
$71,812 |
D/D |
43,100 |
0 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2004-11-19 |
4 |
S |
$3.50 |
$140,375 |
D/D |
(40,000) |
0 |
|
- |
|
| Goodenew Robert S |
V.P. Corporate Development |
• – – |
2004-11-19 |
4 |
OE |
$1.00 |
$46,400 |
D/D |
40,000 |
40,000 |
|
- |
|
| Rabussay Dietmar P |
V.P. Research & Development |
• – – |
2004-11-11 |
4 |
S |
$3.41 |
$853 |
D/D |
(250) |
17,386 |
|
- |
|
505 Records found
|
|
Page 20 of 21 |
|
|
